- Policy
- Severe asthma txs Nucala and Cinqair are to be reimbursed
- by Lee, Jeong-Hwan Oct 24, 2023 05:22am
- Reimbursement treatment options for the treatment of severe eosinophilic asthma are expanded. GSK Korea's Nucala and Handok Teva Cinqair will be listed on the payroll simultaneously next month. Eisai's JAK inhibitor Jyseleca will also have new insurance coverage standards, and Novartis' JAK1/JAK2 inhibitor Jakavi will have coverage standards
- Policy
- TZD combined DPP4i-SGLT2i complex
- by Lee, Tak-Sun Oct 24, 2023 05:21am
- Due to the expansion of the reimbursement standards for combination diabetes drugs, combination drugs combining TZD-based ingredients with DPP4i or SGLT2i are expected to be released in November. Most of these products are combination drugs combining the DPP4i series Sitagliptin. According to the industry on the 23rd, TZD combination drugs s
- Policy
- Announcement of dual pricing system
- by Lee, Jeong-Hwan Oct 20, 2023 05:32am
- The Ministry of Health and Welfare is expected to include the application of a refund-type risk-sharing system for innovative new drugs in the plan to provide appropriate information on the innovative value of new drugs to be announced soon. In order to improve accessibility to rare disease treatments, the company announced its position to c
- Policy
- Will a new Alzheimer’s drug be introduced in 20 yrs in KOR?
- by Lee, Tak-Sun Oct 20, 2023 05:31am
- New Alzheimer's disease treatments are accelerating their introduction into the country. Following Eisai's application for the approval of its ‘lecanemab’ in June, Lilly also received approval from the Ministry of Food and Drug Safety to initiate a multinational Phase 3 clinical trial for ‘donanemab’ in Korea. As Biogen applied to
- Policy
- HIRA ‘will discuss reimb obesity treatments with MOHW'
- by Lee, Tak-Sun Oct 19, 2023 05:29am
- In response to the claim that obesity should be recognized as a chronic disease and its treatment covered by Korea’s health insurance, President Jung-gu Kang of the Health Insurance Review and Assessment Service responded that he would discuss the request with the Ministry of Health and Welfare. Kang made this announcement at the Natio
- Policy
- NA calls for prompt reimb of Ilaris during NA audit
- by Lee, Tak-Sun Oct 19, 2023 05:29am
- The National Assembly requested progress to be made in reimbursing ‘Ilaris (canakinumab, Novartis),’ a drug used to treat Hereditary recurrent fever syndromes that affect 13 patients in Korea. Rep. Sun-Woo Kang of the Democratic Party of Korea and member of the National Assembly Health and Welfare Committee suggested so at the Health I
- Policy
- Rep. Young-hee Choi ‘expenses surged after Moon Care’
- by Lee, Tak-Sun Oct 18, 2023 05:49am
- After the implementation of Moon Jae-in Care, which was implemented to strengthen health insurance coverage, KRW 5.272 trillion was found to have been spent on drugs for seriously ill patients over the 6 years and exceeded the expenditure target every year. According to data Rep. Choi Young-hee (People Power Party, proportional representa
- Policy
- Layla+Celecoxib coming soon
- by Lee, Tak-Sun Oct 18, 2023 05:48am
- A compound that combines different osteoarthritis treatments based on natural products and synthesis is expected to be released on the 1st of next month. 20 companies are selling their products, and it is noteworthy whether it will create a new wind in the osteoarthritis treatment market. The original drug ingredient of Danggui, Mogwa, Bangp
- Policy
- Pharma-Bio Control Tower launched…first meeting next month
- by Lee, Jeong-Hwan Oct 18, 2023 05:48am
- A presidential order to establish the Biohealth Innovation Committee, a control tower to foster the pharmaceutical bio-industry, has been issued. The government plans to hold its first meeting next month to begin discussing major agendas. With the launch of a pan-ministerial organization, financial and administrative support is expected to be
- Policy
- Daewoong's new diabetes drug 'Envlo',
- by Lee, Tak-Sun Oct 17, 2023 05:28am
- Envlo, a new diabetes drug developed by Daewoong Pharmaceutical, is entering long-term safety and efficacy testing of the Zemiglo three-drug therapy. While triple therapy of the Metformin+SGLT2i+DPP4i has been approved for reimbursement since last April, Daewoong Pharmaceutical is expected to establish its position as a latecomer, Envlo, in
